Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.33. Which is the better fit depends on your goals.
| VRTX | VWO | |
|---|---|---|
Market Cap | $132.79B | — |
Sector | Health | — |
52-Week High | $529.65 | $61.24 |
52-Week Low | $376.62 | $51.20 |
Enterprise Value | $126.92B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VWO trades at $60.47, up 0.85% today, with a bullish technical signal from moving averages but overbought RSI levels. The ETF offers low-cost exposure to emerging markets with a 0.06% expense ratio and a 2.4% dividend yield, attracting institutional inflows as seen in recent SEC filings. Recent news highlights strong investor interest in emerging markets ex-China and AI-driven growth in regions like Taiwan and Thailand.
Outlook is positive due to record capital flows into emerging markets and diversification benefits, but risks include China's economic volatility and currency fluctuations. The ETF's low fees and focus on high-growth economies support long-term potential, though short-term technical indicators suggest caution near resistance at $61.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
